On September 22, 2025, Avenzo Therapeutics, Inc., a clinical-stage biotechnology company developing next-generation oncology therapies, announced the closing of a $60 million Series B financing. The financing was led by OrbiMed and SR One, with participation from new investor Longwood Fund. Wilson Sonsini Goodrich & Rosati advised co-lead investor SR One on the transaction.

In addition, all existing investors, including Foresite Capital, Lilly Asia Ventures, Surveyor Capital (a Citadel company), New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, and Quan Capital, participated in this financing.

This funding, which follows Avenzo’s $386 million Series A/A-1 announced in November 2024, will be used to support the advancement of Avenzo’s pipeline of potential best-in-class oncology drug candidates.

The Wilson Sonsini team that advised SR One on the transaction includes Dan Koeppen and Kassandra Castillo.

For more information, please see the press release.